Skip to main content
MedPathMedPath Home
Clinical Trials/2024-515913-17-00
2024-515913-17-00
Not yet recruiting
Phase 2

SPI-62 as a Treatment for Adrenocorticotropic Hormone- dependent Cushing’s Syndrome

Sparrow Pharmaceuticals Inc., Sparrow Pharmaceuticals Inc.4 sites in 2 countries9 target enrollmentStarted: October 1, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Sparrow Pharmaceuticals Inc., Sparrow Pharmaceuticals Inc.
Enrollment
9
Locations
4
Primary Endpoint
The urinary HSD-1 ratio ([tetrahydrocortisol + allotetrahydrocortisol]/tetrahydrocortisone) at Week 6 in subjects with Cushing's disease.
OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

To characterize the pharmacologic effect of SPI-62 in subjects with ACTH-dependent Cushing's syndrome including Cushing's disease, ectopic ACTH secretion, and ectopic corticotrophin-releasing hormone (CRH) secretion, as measured using the urinary 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) ratio.

Study Design

Allocation
Randomized
Primary Purpose
Spi-62 As A Treatment For Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Masking
Double (Subject, Investigator)

Eligibility Criteria

Ages
18 years to 64 years (18-64 Years)
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Male or female aged 18 years or older.
  • •Able to provide written informed consent.
  • •Active and consistent cortisol excess: a. Urinary free cortisol UFC > upper limit of normal (ULN) based on at least 2 valid (i.e., complete) 24-hour urine samples collected during Screening. The subject will be provided collection devices for three 24- hour collections to ensure 2 complete collections are received, particularly if a subject requires washout of other cortisol-suppressing agents. If more than 2 valid collections are received; the mean of all valid completed collections collected after completion of the washout period (if applicable), and available at Day 1 must be >ULN, as confirmed by the central laboratory. Should an additional, otherwise disqualifying, UFC value become available only after Day 1 randomization, the subject will be allowed to continue planned treatment and a sensitivity, per-protocol analysis will be conducted. b. Overnight dexamethasone suppression testing to minimally include a non-suppressed morning serum cortisol ≥ 1.8 mcg/dL (50 nmol/L) after 1 mg ONDST within the last year. c. Late-night/bedtime salivary cortisol above ULN.
  • •Documented diagnosis of ACTH-dependent Cushing's syndrome: This includes Cushing's disease, ectopic ACTH secretion, and ectopic CRH secretion. Subjects may include newly diagnosed subjects who have declined or are not considered candidates for surgery or subjects with residual or recurrent disease after surgery in whom surgery or radiation are not planned within the next 6 months. Previous medical records will be used to support the diagnosis. At least 1 of the following will be considered satisfactory to establish the diagnosis: a. History of positive ACTH-staining pathology. b. History of documented, transient, AI after tumor removal requiring glucocorticoid replacement. c. ACTH level > 20 pg/mL with positive ACTH or cortisol response to CRH or desmopressin (DDAVP) stimulation in the presence of hypercortisolemia. d. Inferior petrosal sinus sampling with ACTH central: plasma gradient ≥ 2 before CRH or DDAVP or ≥ 3 after CRH or DDAVP. e. Presumptive Cushing's disease based on presence of a pituitary tumor ≥ 6 mm along with positive ACTH or cortisol response to CRH or DDAVP stimulation or an overnight or high-dose (8 mg) dexamethasone suppression of cortisol, performed and interpreted according to locally recognized standards of diagnosis f. In the absence of any of the above, an individual might be eligible if ectopic ACTH-dependent Cushing's syndrome was otherwise confirmed via adequate testing consistent with the local standards of care. Such cases must be discussed with and explicitly approved by the Medical Monitor and Sponsor, and the specific diagnostic criteria used to establish the diagnosis of ACTH-dependent Cushing's syndrome must be documented.
  • •Willing to comply with reproductive precautions: Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception as detailed in Appendix
  • •Current evidence of Cushing's morbidities of hyperglycemia, dyslipidemia, hypertension, or osteopenia: Defined by having at least 1 of the below criteria, ideally including both or either of "a" and "b", but including any of "a", "b", "c" or "d" . a. Diagnosis of insulin-resistance/pre-diabetes or type 2 diabetes: Including subjects on stable diabetic treatment, but excluding those ethically requiring further or frequent therapy adjustments. Type 2 diabetes is defined as a current HbA1c ≥ 6.5% but ≤ 9.5% (otherwise excluded), fasting blood glucose (FBG) > 126 mg/dL, or 2 hr OGTT ≥ 200 mg/dL. Pre-diabetes is defined as current HbA1c < 6.5 but > 5.7%, FBG > 100 to 125 mg/dL, or 2-hour OGTT 140 to 199 mg/dL. Insulin-resistance may also be defined by abnormal HOMA-IR >2.5 or by CGM data (e.g., mean glucose, glycemic variability, time in range, estimated HbA1c)²⁸ b. Diagnosis of dyslipidemia: This is evidenced by history of total cholesterol level of ≥ 6.2 mmol/L (240 mg/dL) or triglycerides of ≥ 5.2 mmol/L (200 mg/dL) Current total cholesterol may be < 6.2 mmol/L, and current triglycerides may be < 5.2 mmol/L, if controlled with allowed lipid-lowering therapy. c. Diagnosis of hypertension: Incident hypertension should be brought under control and stabilized prior to randomization at Day
  • •Subjects with hypertension which is reasonably, but sub-optimally managed by standard therapy at baseline (systolic blood pressure [SBP] >140 but < 180 or DBP > 90 but < 120 mmHg) qualify. d. Diagnosis of osteoporosis or osteopenia: Osteopenia (T-score ≤ -1.0 or Z-score ≤ -2.0) or osteoporosis as determined previously, during by the site's local Baseline DEXA reading or history or evidence of minimaltraumatic or osteoporotic fracture treated with lifestyle modification with mineral or vitamin supplementation or stable approved osteoporosis therapies.

Exclusion Criteria

  • •Recent or planned Cushing's surgery: Surgery for Cushing's within the past 6 months or planned within 24 weeks after randomization.
  • •Uncontrolled Cushing's morbidities of hyperglycemia, dyslipidemia, hypertension, or osteopenia: Including evidence of chronic, poor glycemic control (HbA1c > 9.5%), symptomatic dyslipidemia (e.g., hypercholesterolemia with recent (< 1 year) cerebro- or cardiovascular events, hypertriglyceridemia with pancreatitis), persistent uncontrolled hypertension (systolic blood pressure > 180 mmHg or DBP > 120 mmHg), or recent (< 1 year) osteoporotic fracture ethically requiring additional medical intervention.
  • •Use of drugs likely to interfere with study assessments: These include chronic systemic corticosteroids, thiazolidinediones, drugs that may alter the metabolism and clearance of corticosteroids (e.g., 5- alpha-reductase inhibitors), supplements or traditional medicines that contain a HSD-1 inhibitor, within 12 weeks prior to the first dose of study drug. See Section 6.1 Concomitant Medications for recommendations regarding use of certain other allowed medications
  • •Uncontrolled hypothyroidism or hyperthyroidism.
  • •Moderate or severe renal impairment: Defined by an estimated glomerular filtration rate (GFR) repeatedly < 60 mL/min/1.73 m2 or confirmed by measured GFR < 60 mL/min/1.73 m2.In the long-term phase of study, patients having function decline to < 45 mL/min/1.73 m2 should be withdrawn from the study unless formal renal-impairment
  • •Medically significant liver disease Including cirrhosis, chronic active hepatitis, chronic persistent hepatitis, or subjects with serum total bilirubin > 1.5 × ULN (unless previously diagnosed with benign Gilbert's disease) or serum ALT or AST >3 × ULN.
  • •Medically significant cardiovascular or ECG abnormalities: This includes subjects with recent (< 1 year) myocardial infarction or stroke, orthostatic or vasovagal syncope, QT interval corrected (QTc) intervals > 500 ms, or evidence of significant, life-threatening arrhythmia or bradycardia (HR < 45 bpm).
  • •History of idiopathic thrombocytopenic purpura.
  • •History of adrenal carcinoma.
  • •Recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) infection: Positive test for infection within the past 4 weeks or hospitalization for coronavirus disease 2019 (COVID-19) within the past 6 months.

Outcomes

Primary Outcomes

The urinary HSD-1 ratio ([tetrahydrocortisol + allotetrahydrocortisol]/tetrahydrocortisone) at Week 6 in subjects with Cushing's disease.

The urinary HSD-1 ratio ([tetrahydrocortisol + allotetrahydrocortisol]/tetrahydrocortisone) at Week 6 in subjects with Cushing's disease.

Secondary Outcomes

  • 1. Adverse events, including clinically significant abnormal values on clinical laboratory evaluations (clinical chemistry, hematology, and urinalysis), continuous glucose monitoring (CGM), 12-lead ECGs, vital signs measurements (including orthostatic vital sign measurements), physical examinations, and clinically significant changes from baseline, for HPA and HPG axis biomarkers (ACTH, serum cortisol, free cortisol, cortisone, arginine vasopressin [AVP], testosterone, estradiol, dehydroepiandro
  • 2. Clinical laboratory evaluations, ECG intervals, pulse, temperature, and HPA and HPG axis biomarkers at Week 6, as well as changes from baseline during 12 weeks of SPI-62 administration, will be described.
  • 3. Long-term safety, including assessments of longer-term will be monitored in the open-label extension phase of this trial.
  • 4. Glucose AUC during oral glucose tolerance test (OGTT) and OGTTCGM, other CGM parameters (e.g., CGM time > 140 and > 200 mg/dL, among others), HbA1c, insulin, fasting plasma glucose, body weight, body mass index, dual energy x-ray absorptiometry (DEXA) scan results (body fat and muscle content [including total body, trunk, abdominal, head/neck, supraclavicular and hepatic fat content], bone-mineral density [T- and Zscores] and trabecular bone score), bone markers [osteocalcin, procollagen I N-
  • 5. Performance on muscle strength (Timed Up and Go-Chair Stand [TUGCS], hand grip strength [HGS] tests), and scores on Symptoms of Major Depressive Disorder Scale (SMDDS), Short Form Survey-36 version 2 (SF-36v2), Medical Outcomes Study Sleep Scale-Revised (MOS-Sleep-R), pain numeric rating scale (NRS), and Patient Global Impression of Severity(PGI-S)/Patient Global Impression of Change (PGI-C) at Week 6, as well as change from baseline during 6 and 12 weeks of SPI-62 administration, will be des
  • 6. Proportions of subjects with urinary HSD-1 ratio ≤ 0.7 and ≤ 0.2 at Week 6 will be reported.
  • 7. Change from baseline during 6 and 12 weeks of SPI-62 administration on urinary HSD-1 ratio will be described.
  • 8. 24-hour UFC and steroid profile, and spot urine for the urinary ratio cortisone/cortisol at Week 6, as well as change from baseline during 6 and 12 weeks of SPI-62 administration, will be described.
  • 9. Changes in Cushing's phenotypic features will be tabulated (Appendix 7) and monitored into the long-term extension trial (except for photography).
  • 10. The predictive value of urinary HSD-1 ratio at Week 6 for clinical efficacy endpoints will be described.
  • 11. Efficacy analyses will be reported for all evaluable subjects (ITT population), per-protocol subjects and for the subset of evaluable and per-protocol subjects with Cushing's disease.

Investigators

Sponsor
Sparrow Pharmaceuticals Inc., Sparrow Pharmaceuticals Inc.
Sponsor Class
Pharmaceutical company, Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Frank Czerwiec

Scientific

Sparrow Pharmaceuticals Inc.

Study Sites (4)

Loading locations...

Similar Trials

Completed
Phase 2
A trial of prednisolone in combination with SPI-62 or placebo in participants with polymyalgia rheumatica (PMR)
2024-517406-29-00Sparrow Pharmaceuticals Inc.72
Not yet recruiting
Phase 4
Metycor study
2024-514143-28-00Helse Bergen HF100
Completed
Phase 2
This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce glucocorticoid use in adult subjects with classic congenital adrenal hyperplasia who are on supraphysiologic doses of glucocorticoid therapy.
2023-503771-13-00Spruce Biosciences Inc.44
Recruiting
Not Applicable
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
NCT07261644Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.500
Recruiting
Phase 3
HydroxyChloroquine as steroid-sparing Agent in Extra-pulmonary SARcoidosis. A multicenter, prospective, placebo-controlled, randomized trial. CAESAR
2022-502155-65-00Hospices Civils De Lyon140